bioMerieux and Ipsen Sign Theragnostics Agreement to Develop Companion Test for new Breast Cancer Treatment
Complete the form below to unlock access to ALL audio articles.
bioMerieux and Ipsen announced that they have signed an agreement by which bioMerieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen. The development will be co-funded by bioMerieux and Ipsen.
Ipsen is developing a breast cancer therapy, BN 83495, targeting the steroid sulfatase enzyme (STS). The new drug, designed to block this marker found in hormone-dependent breast cancer in postmenopausal women, is currently in phase I clinical development.
bioMerieux will devise a companion assay to determine the patients best suited to benefit from the new STS inhibitor treatment. The assay is intended for both the clinical development of the Ipsen drug as well as a diagnostic test, potentially for future commercialization. The test will be developed on bioMerieux’s NucliSENS EasyQ® molecular diagnostics platform, using the company’s proprietary NASBA® amplification technology.
“bioMerieux is very pleased to sign an important theragnostics partnership with Ipsen and bring a high medical value test to help advance cancer treatment options and improve patient prognosis,” declared Stephane Bancel, Chief Executive Officer of bioMerieux. “By teaming our expertise with that of biopharmaceutical companies, bioMerieux’s goal is to contribute towards making the best medicine available to the right patients, while optimizing health costs,” he added.
